Next Article in Journal
Sex Differences in the Presence and Severity of Alcohol Hangover Symptoms
Next Article in Special Issue
Comparison of Oncologic Outcomes in Laparoscopic versus Open Surgery for Non-Metastatic Colorectal Cancer: Personal Experience in a Single Institution
Previous Article in Journal
The Role of Genetic Factors in Characterizing Extra-Intestinal Manifestations in Crohn’s Disease Patients: Are Bayesian Machine Learning Methods Improving Outcome Predictions?
Previous Article in Special Issue
Efficacy and Safety of Ceftaroline for the Treatment of Community-Acquired Pneumonia: A Systemic Review and Meta-Analysis of Randomized Controlled Trials
Article

The Efficacy and Safety of Eravacycline in the Treatment of Complicated Intra-Abdominal Infections: A Systemic Review and Meta-Analysis of Randomized Controlled Trials

1
School of Pharmaceutical Sciences and Medical Technology, Putian University, Putian 351100, Fujian, China
2
Department of Pharmacy, Chi Mei Medical Center, Liouying 73657, Taiwan
3
Department of Intensive Care Medicine, Chi Mei Medical Center, Liouying 73657, Taiwan
4
School of Management, Putian University, Putian 351100, China
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2019, 8(6), 866; https://doi.org/10.3390/jcm8060866
Received: 27 May 2019 / Revised: 12 June 2019 / Accepted: 13 June 2019 / Published: 17 June 2019
(This article belongs to the Special Issue Clinical Medicine for Healthcare and Sustainability)
This study aims to assess the clinical efficacy and safety of eravacycline for treating complicated intra-abdominal infection (cIAI) in adult patients. The PubMed, Web of Science, EBSCO, Cochrane databases, Ovid Medline, Embase, and ClinicalTrials.gov were searched up to May 2019. Only randomized controlled trials (RCTs) that evaluated eravacycline and other comparators for the treatment of cIAI were included. The primary outcome was the clinical cure rate at the test-of-cure visit based on modified intent-to-treat population, microbiological intent-to-treat population, clinically evaluable population, and microbiological evaluable population, and the secondary outcomes were clinical failure rate and the risk of adverse event. Three RCTs were included. Overall, eravacycline had a clinical cure rate (88.7%, 559/630) at test-of-cure in modified intent-to-treat population similar to comparators (90.1%, 492/546) in the treatment of cIAIs (risk ratio (RR), 0.99; 95% confidence interval (CI), 0.95–1.03; I2 = 0%, Figure 3). In the microbiological intent-to-treat, clinically evaluable, and microbiological evaluable populations, no difference was found between eravacycline and comparators in terms of clinical cure rate at test-of-cure (microbiological intent-to-treat population, RR, 0.99; 95% CI, 0.95–1.04; I2 = 0%, clinically evaluable population, RR, 1.00; 95% CI, 0.97–1.03; I2 = 0%, microbiological evaluable population, RR, 0.98; 95% CI, 0.95–1.02; I2 = 0%). In addition, eravacycline had clinical failure rate similar to comparators at test-of-cure in modified intent-to-treat population (RR, 1.01; 95% CI, 0.61–0.69; I2 = 0%), microbiological intent-to-treat population (RR, 1.34; 95% CI, 0.77–2.31; I2 = 16%), clinically evaluable population (RR, 1.03; 95% CI, 0.61–1.76; I2 = 0%), and microbiological evaluable population (RR, 1.32; 95% CI, 0.75–2.32; I2 = 10%). Although eravacycline was associated with higher risk of treatment-emergent adverse event than comparators (RR, 1.34; 95% CI, 1.13–1.58; I2 = 0%), no significant differences were found between eravacycline and comparators for the risk of serious adverse event (RR, 1.04; 95% CI, 0.65–1.65; I2 = 0%), discontinuation of study drug because of adverse event (RR, 0.68; 95% CI, 0.23–1.99; I2 = 13%), and all-cause mortality (RR, 1.09; 95% CI, 0.41–2.9; I2 = 28%). In conclusion, the clinical efficacy of eravacycline is as high as that of the comparator drugs in the treatment of cIAIs and this antibiotic is as well tolerated as the comparators. View Full-Text
Keywords: eravacycline; complicated intra-abdominal infection; efficacy; safety; mortality eravacycline; complicated intra-abdominal infection; efficacy; safety; mortality
Show Figures

Figure 1

MDPI and ACS Style

Lan, S.-H.; Chang, S.-P.; Lai, C.-C.; Lu, L.-C.; Chao, C.-M. The Efficacy and Safety of Eravacycline in the Treatment of Complicated Intra-Abdominal Infections: A Systemic Review and Meta-Analysis of Randomized Controlled Trials. J. Clin. Med. 2019, 8, 866. https://doi.org/10.3390/jcm8060866

AMA Style

Lan S-H, Chang S-P, Lai C-C, Lu L-C, Chao C-M. The Efficacy and Safety of Eravacycline in the Treatment of Complicated Intra-Abdominal Infections: A Systemic Review and Meta-Analysis of Randomized Controlled Trials. Journal of Clinical Medicine. 2019; 8(6):866. https://doi.org/10.3390/jcm8060866

Chicago/Turabian Style

Lan, Shao-Huan, Shen-Peng Chang, Chih-Cheng Lai, Li-Chin Lu, and Chien-Ming Chao. 2019. "The Efficacy and Safety of Eravacycline in the Treatment of Complicated Intra-Abdominal Infections: A Systemic Review and Meta-Analysis of Randomized Controlled Trials" Journal of Clinical Medicine 8, no. 6: 866. https://doi.org/10.3390/jcm8060866

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop